Feed Top Reports Pricing

⌘K

11:55:59·17d

SECFiling

SEC Form DEFA14A filed by AtriCure Inc.

ATRC· AtriCure Inc.

Health Care

Original source

Companies

ATRC
AtriCure Inc.
Health Care

Recent analyst ratings

Feb 18UpdateOppenheimer-
Feb 11UpdateAnalyst$36.00
Dec 17UpdateAnalyst$40.00
Apr 23UpdateOppenheimer$32.00
Oct 23UpdateJMP Securities$60.00
Sep 29UpdateUBS$56.00

Related

PR9d
AtriCure to Announce First Quarter 2026 Financial Results
SEC17d
SEC Form DEF 14A filed by AtriCure Inc.
SEC28d
Amendment: SEC Form SCHEDULE 13G/A filed by AtriCure Inc.
INSIDER38d
Chief Scientific Officer Doraiswamy Vinayak sold $149,150 worth of shares (5,000 units at $29.83), decreasing direct ownership by 5% to 96,875 units (SEC Form 4)
INSIDER42d
Director White Robert S. exercised 10,000 shares at a strike of $14.99, increasing direct ownership by 9% to 122,174 units (SEC Form 4)
INSIDER45d
President, CEO, & Director Carrel Michael H gifted 6,000 shares, decreasing direct ownership by 0.76% to 778,498 units (SEC Form 4)
INSIDER51d
Chief Scientific Officer Doraiswamy Vinayak was granted 45,588 shares and covered exercise/tax liability with 15,585 shares, increasing direct ownership by 42% to 101,875 units (SEC Form 4)
INSIDER51d
Chief Mktg & Strategy Officer Noznesky Justin J was granted 43,189 shares and covered exercise/tax liability with 15,586 shares, increasing direct ownership by 35% to 106,401 units (SEC Form 4)

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releases Analyst ratings Insider trading FDA SEC RSS feeds

Top lists

Trending By market cap Active companies Analyst upgrades Insider purchases FDA approvals SEC filings Sectors Market reports

Company

About Pricing Publish with us Contact

Legal

Terms of use Privacy policy Cookie policy

© 2026 quantisnow.com · Democratizing insights since 2022